Citi Comments on Apellis Pharmaceuticals (APLS), Moves PT to $106
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Apellis Pharmaceuticals (APLS) PT Raised to $114 at BofA Securities
May 5, 2023 9:38 AM EDTBofA Securities analyst Tazeen Ahmad raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $114.00 (from $112.00) while maintaining a Buy rating.... More
Apellis Pharmaceuticals (APLS) PT Raised to $90 at Stifel
May 5, 2023 8:25 AM EDTStifel analyst Annabel Samimy raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $90.00 (from $75.00) while maintaining a Buy rating.... More
Apellis Pharmaceuticals (APLS) PT Raised to $110 at Needham & Company
May 5, 2023 7:56 AM EDTNeedham & Company analyst Joseph Stringer raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $110.00 (from $80.00) while maintaining a Buy rating.... More
Apellis Pharmaceuticals (APLS) PT Raised to $156 at Raymond James
May 5, 2023 7:37 AM EDTRaymond James analyst Steven Seedhouse raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $156.00 (from $139.00) while maintaining a Strong Buy rating.... More
Apellis Pharmaceuticals (APLS) PT Raised to $76 at Wells Fargo
May 5, 2023 6:46 AM EDTWells Fargo analyst Derek Archila raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $76.00 (from $55.00) while maintaining a Equal Weight rating.... More
Apellis Pharmaceuticals (APLS) PT Raised to $81 at Credit Suisse
May 5, 2023 5:54 AM EDTCredit Suisse analyst Tiago Fauth raised the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $81.00 (from $70.00) while maintaining a Neutral rating.... More
After-hours movers: Apple gains on surprise beat, Lyft tumbles
May 4, 2023 5:39 PM EDTAfter-Hours Stock Movers:
Trupanion (NASDAQ: TRUP) 27% LOWER; reported Q1 EPS of ($0.60), $0.33 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $256.3 million versus the consensus estimate of $251.68 million.
Carvana Co. (NYSE: CVNA) 24% HIGHER; reported Q1 Revenue for the quarter at $2.61 billion versus the consensus estimate of $2.66 billion. The company expects to achieve positive adjusted EBITDA in Q2.
Clearfield, Inc. (NASDAQ:... More
Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 10c
May 4, 2023 4:46 PM EDTApellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of $1.56, $0.10 worse than the analyst estimate of $1.66. Revenue for the quarter came in at $44.84 million versus the consensus estimate of $26.1 million.
For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.
... More